TABLE II.
The duration of treatment with dorzolamide, foveal zone thickness (FZT) in each eye before the start of treatment and at the time of final response, the percentage change in FZT from baseline and the qualitative improvement on OCT as judged by the authors.
| S.No | Time (months) |
FZT OD-start |
FZT OS-start |
FZT OD- response |
FZT OS- response |
FZT OD- % change |
FZT OS- % change |
OD- Qualitative change |
OS- Qualitative change |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 15 | 323 | 218 | 230 | 133 | 28.79 | 38.99 | 3.5 | 4 |
| 2 | 2 | 255 | 231 | 392 | 356 | −53.72 | −54.11 | 0 | 0 |
| 3 | 26 | 315 | 262 | 162 | 171 | 48.57 | 34.73 | 4 | 4 |
| 4 | 26 | 664 | 606 | 164 | 167 | 75.3 | 72.44 | 4 | 4 |
| 5 | 18 | 416 | 395 | 178 | 176 | 57.21 | 55.44 | 4 | 4 |
| 6 | 23 | 525 | 551 | 431 | 153 | 17.9 | 72.23 | 3 | 4 |
| 7 | 6.5 | not treated | 272 | not treated | 170 | - | 37.5 | - | 4 |
Patients 1 &2 are siblings.